Proton Therapy For Lymphomas: Current State Of The Art

Umberto Ricardi,1 Maja V Maraldo,2 Mario Levis,1 Rahul R Parikh3 1Department of Oncology, University of Torino, Torino, Italy; 2Department of Clinical Oncology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark; 3Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey, N...

Full description

Bibliographic Details
Main Authors: Ricardi U, Maraldo MV, Levis M, Parikh RR
Format: Article
Language:English
Published: Dove Medical Press 2019-10-01
Series:OncoTargets and Therapy
Subjects:
Online Access:https://www.dovepress.com/proton-therapy-for-lymphomas-current-state-of-the-art-peer-reviewed-article-OTT
id doaj-c20a7828bfe34aeab826b604c24ea70c
record_format Article
spelling doaj-c20a7828bfe34aeab826b604c24ea70c2020-11-24T20:46:38ZengDove Medical PressOncoTargets and Therapy1178-69302019-10-01Volume 128033804648890Proton Therapy For Lymphomas: Current State Of The ArtRicardi UMaraldo MVLevis MParikh RRUmberto Ricardi,1 Maja V Maraldo,2 Mario Levis,1 Rahul R Parikh3 1Department of Oncology, University of Torino, Torino, Italy; 2Department of Clinical Oncology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark; 3Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USACorrespondence: Mario LevisDepartment of Oncology, University of Torino, Via Genova 3, Torino 10125, ItalyTel +39 011 6334119Fax +39 011 6336614Email mario.levis@unito.itAbstract: The combination of brief chemo-radiotherapy provides high cure rates and represents the first line of treatment for many lymphoma patients. As a result, a high proportion of long-term survivors may experience treatment-related toxic events many years later. Excess and unintended radiation dose to organs at risk (particularly heart, lungs and breasts) may translate in an increased risk of cardiovascular events and second cancers after a few decades. Minimizing dose to organs at risk is thus pivotal to restrain the risk of long-term complications. Proton therapy, with its peculiar physic properties, may help to better spare organs at risk and consequently to reduce toxicities especially in patients receiving mediastinal radiotherapy. Herein, we review the physical basis of proton therapy and the rationale for its implementation in lymphoma patients, with a detailed description of the clinical data. We also discuss the potential disadvantages and uncertainties of protons that may limit their application and critically review the dosimetric studies comparing the risk of late complications between proton and photon radiotherapy.Keywords: proton therapy, lymphoma, Hodgkin, radiotherapyhttps://www.dovepress.com/proton-therapy-for-lymphomas-current-state-of-the-art-peer-reviewed-article-OTTProton therapylymphomaHodgkinradiotherapy
collection DOAJ
language English
format Article
sources DOAJ
author Ricardi U
Maraldo MV
Levis M
Parikh RR
spellingShingle Ricardi U
Maraldo MV
Levis M
Parikh RR
Proton Therapy For Lymphomas: Current State Of The Art
OncoTargets and Therapy
Proton therapy
lymphoma
Hodgkin
radiotherapy
author_facet Ricardi U
Maraldo MV
Levis M
Parikh RR
author_sort Ricardi U
title Proton Therapy For Lymphomas: Current State Of The Art
title_short Proton Therapy For Lymphomas: Current State Of The Art
title_full Proton Therapy For Lymphomas: Current State Of The Art
title_fullStr Proton Therapy For Lymphomas: Current State Of The Art
title_full_unstemmed Proton Therapy For Lymphomas: Current State Of The Art
title_sort proton therapy for lymphomas: current state of the art
publisher Dove Medical Press
series OncoTargets and Therapy
issn 1178-6930
publishDate 2019-10-01
description Umberto Ricardi,1 Maja V Maraldo,2 Mario Levis,1 Rahul R Parikh3 1Department of Oncology, University of Torino, Torino, Italy; 2Department of Clinical Oncology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark; 3Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USACorrespondence: Mario LevisDepartment of Oncology, University of Torino, Via Genova 3, Torino 10125, ItalyTel +39 011 6334119Fax +39 011 6336614Email mario.levis@unito.itAbstract: The combination of brief chemo-radiotherapy provides high cure rates and represents the first line of treatment for many lymphoma patients. As a result, a high proportion of long-term survivors may experience treatment-related toxic events many years later. Excess and unintended radiation dose to organs at risk (particularly heart, lungs and breasts) may translate in an increased risk of cardiovascular events and second cancers after a few decades. Minimizing dose to organs at risk is thus pivotal to restrain the risk of long-term complications. Proton therapy, with its peculiar physic properties, may help to better spare organs at risk and consequently to reduce toxicities especially in patients receiving mediastinal radiotherapy. Herein, we review the physical basis of proton therapy and the rationale for its implementation in lymphoma patients, with a detailed description of the clinical data. We also discuss the potential disadvantages and uncertainties of protons that may limit their application and critically review the dosimetric studies comparing the risk of late complications between proton and photon radiotherapy.Keywords: proton therapy, lymphoma, Hodgkin, radiotherapy
topic Proton therapy
lymphoma
Hodgkin
radiotherapy
url https://www.dovepress.com/proton-therapy-for-lymphomas-current-state-of-the-art-peer-reviewed-article-OTT
work_keys_str_mv AT ricardiu protontherapyforlymphomascurrentstateoftheart
AT maraldomv protontherapyforlymphomascurrentstateoftheart
AT levism protontherapyforlymphomascurrentstateoftheart
AT parikhrr protontherapyforlymphomascurrentstateoftheart
_version_ 1716812066105327616